NEW YORK (GenomeWeb News) – Oncology diagnostics company Biocept said on Friday that its revenues for 2013 increased 23 percent year over year.

For full-year 2013, revenues rose to $134,245 from $109,289 in 2012, the San Diego-based firm said in its Form 10-K filed with the US Securities and Exchange Commission. Its net loss in 2013 was $9.2 million, or $50.80 per share, compared to a net loss of $12.3 million, or $76.43 per share, in 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.